Leqvio Demonstrates Significant Reduction of LDL-C in Patients at Risk for Atherosclerotic Cardiovascular Disease

Topline results from Leqvio’s Phase 3 V-MONO trial found that twice-yearly dosing of Leqvio resulted in clinically meaningful LDL-C reductions compared with both placebo and ezetimibe.